BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28782811)

  • 21. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
    Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.
    Zheng W; Liu M; Guan L; Wang S
    Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival after histologic transformation of low-grade follicular lymphoma.
    Yuen AR; Kamel OW; Halpern J; Horning SJ
    J Clin Oncol; 1995 Jul; 13(7):1726-33. PubMed ID: 7602362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
    Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
    Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.
    Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E
    Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
    Hirayama Y; Ishitani K; Ota S; Kurosawa M; Kondo T; Takimoto R; Mori A; Sakai H; Torimoto Y; Yamamoto S; Sato K; Iwasaki H; Kohda K; Ishida T; Kakinoki Y; Fukuhara T; Kato J
    Int J Hematol; 2014 Sep; 100(3):281-9. PubMed ID: 25052874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
    Conconi A; Ponzio C; Lobetti-Bodoni C; Motta M; Rancoita PM; Stathis A; Moccia AA; Mazzucchelli L; Bertoni F; Ghielmini M; Cavalli F; Zucca E
    Br J Haematol; 2012 Apr; 157(2):188-96. PubMed ID: 22348437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
    Magnano L; Alonso-Alvarez S; Alcoceba M; Rivas-Delgado A; Muntañola A; Nadeu F; Setoain X; Rodríguez S; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Sancho JM; Moreno M; Mercadal S; Carro I; Salar A; Garcia-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Jiménez-Ubieto A; Rodriguez A; González de Villambrosía S; Bello JL; López L; Novelli S; de Cabo E; Infante ME; Pardal E; Monsalvo S; González M; Martín A; Caballero MD; López-Guillermo A;
    Br J Haematol; 2019 May; 185(3):480-491. PubMed ID: 30793290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
    Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
    J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
    Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
    Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 40. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
    Madsen C; Clausen MR; Plesner TL; Pasanen A; Kuismanen T; Bentzen HH; Jørgensen JM; Sillesen IB; Himmelstrup BM; Rønnov-Jessen D; Jensen KR; Pettinger AM; Ludvigsen M; Leppä S; d'Amore FA
    Blood Adv; 2018 Jul; 2(13):1562-1571. PubMed ID: 29976619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.